Trends & Analysis

#Clinical trial #Diabetes #Drug development #GlobalData #Type 2 diabetes

Eli Lilly’s tirzepatide continues to outperform popular diabetes drugs

Eli Lilly’s tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able to not only reduce HbA1c levels in type 2 diabetes (T2D) patients, but also confer weight loss when compared to insulin glargine in the SURPASS-4 trial. Tirzepatide… Read More

#News #Trends & Analysis

#3D modelling #Antibiotics #Biotechnology #Cell / tissue culture #Data #Drug discovery #Drug targets #Drug technology #Imaging

How imaging techniques are innovating drug discovery

Lu Rahman takes look at some of the latest imaging innovation available and how it can benefit drug target identification and drug discovery research. Imaging is an important element within the drug discovery and development process providing researchers with information that can help identify potential drug targets or see how… Read More

#Exclusive Content #News #Trends & Analysis

#AI / data analytics / healthtech / informatics #Diabetes #Drug development #Precision medicine

The power of precision medicine

Listen to this article on the DDW Podcast: Lu Rahman looks at the role precision medicine is playing in how we approach the patient and the way we  treat disease. We hear increasingly about the shift away from one size fits all medicine. It does of course, make perfect… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis

#AI / data analytics / healthtech / informatics #Drug discovery

Precision medicine in the era of artificial intelligence

Dr Lotfi Chouchane and Dr. Javaid Sheikh, Weill Cornell Medicine-Qatar, outline the challenges and opportunities ahead for drug discovery Precision medicine is an emerging model for the next generation of clinical care that will capitalise on the dynamic interaction between individual biology, lifestyle, behaviour, and environment. It holds huge promise… Read More

#Exclusive Content #News #Trends & Analysis

#Metabolomics #Pharmaceuticals #Research & development

Boosting pharmaceutical research with microbiome data

Microbiome-based evidence is set to drive understanding of how drugs interact with human ‘host’ environments, helping devise more targeted treatments and create business opportunities, reports Anthony Finbow, CEO of Eagle Genomics. The microbiology of the drug recipient impacts their immune response, allergic responses and more. Increasingly, life sciences R&D is… Read More

#Editor's Choice #Exclusive Content #News #Trends & Analysis

#Biotechnology #Cell therapy #Covid-19 #Gene therapy #Immunology / Virology & Vaccines #Pharmaceutical

Investment banking head offers market outlook for 2021

The Jefferies Healthcare Temperature Check report is now in its third edition and published to coincide with the 11th annual Global Healthcare Conference which was held virtually. Over 500 responses from senior leaders in the sector responded for this year’s report, giving views on both the current state of the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #News #Opinion #Trends & Analysis

#Business #Clinical trials #Therapeutics

Drug launches to drive NASH growth across major markets, says research

Several pharmacological treatments for non-alcoholic steatohepatitis (NASH) are expected to be launched in the seven major markets (7MM*) over the next 10 years. It is anticipated that these products can demand higher prices than the current off-label therapies, considering no therapy has been approved for the indication, and drive strong… Read More

#News #Trends & Analysis

#Covid-19 #Pharmaceutical #Research & development

UK pharma sector R&D spending at 8-year high

R&D spending in the UK pharmaceutical sector has jumped 6.9% annually to an eight-year high, analysis of the latest ONS data by R&D tax relief specialist Catax shows. Total pharmaceutical industry spending on R&D rose to £4.8bn last year, an increase of £306m from the £4.5bn recorded a year earlier1. Read More

#Editor's Choice #News #Trends & Analysis

#AI / data analytics / healthtech / informatics #Covid-19 #Drug candidates #Drug development #MS #Therapeutics

New for old: the value behind drug repurposing  

Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially?  More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly,… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#AstraZeneca #Clinical trials #Covid-19 #Drug discovery #Therapeutics #Vaccines

Where are the opportunities in global drug discovery?

With COVID-19 taking centre stage in global drug discovery, Lu Rahman looks at opportunities ahead for the sector and where attention might be focussed going forward.  It is clear from the current pandemic that opportunities arise within drug discovery and development when we don’t always expect… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#Covid-19 #Drug development #Drug discovery #Liverpool

Creating a world leading infection R&D hub in the UK

As the world is rocked by one of the greatest healthcare challenges in living memory, how we treat infectious diseases is becoming one of the key medical questions of our age. Hannah Randles, Health and Life Sciences Champion at Liverpool City Region’s Growth Platform explains how the region’s infectious diseases… Read More

#Covid-19 #Exclusive Content #Trends & Analysis